Periodontal wound healing/regeneration following implantation of recombinant human growth/differentiation factor-5 in a beta-tricalcium phosphate carrier into one-wall intrabony defects in dogs

J Clin Periodontol. 2010 Apr;37(4):382-9. doi: 10.1111/j.1600-051X.2010.01544.x.

Abstract

Objective: Recombinant human growth/differentiation factor-5 (rhGDF-5) is being evaluated as a candidate therapy in support of periodontal regeneration. The objective of this study was to evaluate periodontal wound healing/regeneration following the application of rhGDF-5 on a particulate beta-tricalcium phosphate (beta-TCP) carrier using an established defect model.

Materials and methods: Bilateral 4 x 5 mm (width x depth), one-wall, critical-size, intrabony periodontal defects were surgically created at the mandibular second and fourth pre-molar teeth in 15 Beagle dogs. Unilateral defects in five animals received rhGDF-5/beta-TCP (Scil Technology GmbH); five animals received beta-TCP solo; and five animals served as sham-surgery controls. Contralateral sites received treatments reported elsewhere. The animals were sacrificed following an 8-week healing interval for histological examination.

Results: Clinical healing was generally uneventful. Sites implanted with rhGDF-5/beta-TCP exhibited greater enhanced cementum and bone formation compared with beta-TCP and sham-surgery controls; cementum regeneration averaged (+/- SD) 3.83 +/- 0.73 versus 1.65 +/- 0.82 and 2.48 +/- 1.28 mm for the controls (p<0.05). Corresponding values for bone regeneration height averaged 3.26 +/- 0.30 versus 1.70 +/- 0.66 and 1.68 +/- 0.49 mm (p<0.05), and bone area 10.45 +/- 2.26 versus 6.31 +/- 2.41 and 3.00 +/- 1.97 mm(2) (p<0.05). Cementum regeneration included cellular/acellular cementum with or without a functionally oriented periodontal ligament. A non-specific connective tissue attachment was evident in the sham-surgery control. Controls exhibited mostly woven bone with primary osteons, whereas rhGDF-5/beta-TCP sites showed a noticeable extent of lamellar bone. Sites receiving rhGDF-5/beta-TCP or beta-TCP showed some residual beta-TCP granules apparently undergoing biodegradation without obvious differences between the sites. Sites receiving beta-TCP alone commonly showed residual beta-TCP granules sequestered in the connective tissue or fibrovascular marrow.

Conclusion: rhGDF-5/beta-TCP has a greater potential to support the regeneration of the periodontal attachment. Long-term studies are necessary to confirm the uneventful maturation of the regenerated tissues.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorbable Implants*
  • Alveolar Bone Loss / therapy
  • Alveolar Process / drug effects
  • Alveolar Process / physiology
  • Alveolar Process / surgery
  • Animals
  • Biocompatible Materials / administration & dosage
  • Bone Regeneration / drug effects*
  • Bone Regeneration / physiology
  • Bone Substitutes / administration & dosage
  • Calcium Phosphates / administration & dosage
  • Dental Cementum / drug effects
  • Dental Cementum / physiology
  • Disease Models, Animal
  • Dogs
  • Drug Carriers / administration & dosage
  • Growth Differentiation Factor 5 / administration & dosage
  • Growth Differentiation Factor 5 / physiology*
  • Humans
  • Male
  • Mandible / drug effects
  • Mandible / surgery
  • Osseointegration / drug effects
  • Osseointegration / physiology
  • Periodontal Attachment Loss / drug therapy*
  • Periodontal Ligament / drug effects
  • Periodontal Ligament / physiology
  • Periodontium / drug effects*
  • Periodontium / physiology
  • Recombinant Proteins

Substances

  • Biocompatible Materials
  • Bone Substitutes
  • Calcium Phosphates
  • Drug Carriers
  • Growth Differentiation Factor 5
  • Recombinant Proteins
  • beta-tricalcium phosphate